The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK
Authors:
Open Access
- 29 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (5) , 883-893
Abstract
Pembrolizumab has received approval in the UK as first‐line monotherapy for recurrent and/or metastatic HNSCC (R/M HNSCC) following the results of the KEYNOTE‐048 trial, which demonstrated a longer overall survival (OS) in comparison to the EXTREME chemotherapy regimen in patients with a combined positive score (CPS) ≥1. In this article, we provide retrospective real‐world data on the role of pembrolizumab monotherapy as first‐line systemic therapy for HNSCC across 18 centers in the UK from March 20, 2020 to May 31, 2021. 211 patients were included, and in the efficacy analysis, the objective response rate (ORR) was 24.7%, the median progression‐free survival (PFS) was 4.8 months (95% confidence interval [CI]: 3.6–6.1), and the median OS was 10.8 months (95% CI 9.0–12.5). Pembrolizumab monotherapy was well tolerated, with 18 patients having to stop treatment owing to immune‐related adverse events (irAEs). 53 patients proceeded to second‐line treatment with a median PFS2 of 10.2 months (95% CI: 8.8–11.5). Moreover, patients with documented irAEs had a statistically significant longer median PFS (11.3 vs. 3.3 months; log‐rank p value = <.001) and median OS (18.8 vs. 8.9 months; log‐rank p value <.001). The efficacy and safety of pembrolizumab first‐line monotherapy for HNSCC has been validated using real‐world data.Keywords
This publication has 44 references indexed in Scilit:
- Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time biasCancer Treatment Reviews, 2022
- Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsThe Oncologist, 2021
- Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumabOral Oncology, 2020
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid TumorsAdvances in Therapy, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Biomarkers of response to immune checkpoint blockade in cancer treatmentCritical Reviews in Oncology/Hematology, 2018
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort StudyJournal of Thoracic Oncology, 2017
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 2017
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015